Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD

Current Medical Research and Opinion

Volumn 26, Issue 9, 2010, Pages 2087-2095

  Saylor, Keith ^a   Williams, David W ^b   Schuh, Kory J ^b   Wietecha, Linda ^b   Greenbaum, Michael ^c  

^a NeuroScience Inc   (United States)

^b Lilly USA   (United States)

^c Capstone Clinical Research   (United States)

Author keywords

Adolescents; Atomoxetine; Attention deficit hyperactivity disorder; Behavior; Quality of life; Risk

Indexed keywords

ATOMOXETINE; CENTRAL STIMULANT AGENT;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR; CHILD HEALTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DISEASE SURVEILLANCE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG WITHDRAWAL; FEMALE; HIGH RISK BEHAVIOR; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SELF REPORT; SMOKING; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADOLESCENT BEHAVIOR; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH STATUS; HUMANS; MALE; PROPYLAMINES; QUALITY OF LIFE; RISK-TAKING; SELF CONCEPT;

EID: 77955598637     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.493747     Document Type: Article

References (37)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition. Text revised. Washington, DC: American Psychiatric Association, 2000
2. Kessler RC, Adler L, Ames M, et al. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. J Occup Environ Med 2005;47:565-572
3. Maedgen JW, Carlson CL. Social functioning and emotional regulation in the attention deficit hyperactivity disorder subtypes. J Clin Child Psychol 2000; 29:30-42
4. Pomerleau OF, Downey KK, Stelson FW, et al. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 1995;7:373-378
5. Biederman J, Wilens TE, Mick E, et al. Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol Psychiatry 1998;44:269-273
6. Barkley RA, Murphy KR, DuPaul GI, et al. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc 2002;8:655-672
7. Barkley RA, Fischer M, Smallish L, et al. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 2006;45:192-202
8. Elkins IJ, McGue M, Iacono WG. Prospective effects of attention-deficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse. Arch Gen Psychiatry 2007;64:1145-1152
9. Biederman J, Petty C, Wilens T, et al. Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry 2008; 165:107-115
10. Kollins SH. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. J Atten Disord 2008;12:115-125
11. Jerome L, Segal A, Habinski L. What we know about ADHD and driving risk: a literature review, meta-analysis and critique. J Can Acad Child Adolesc Psychiatry 2006;15:105-125
12. Thompson AL, Molina BS, Pelham Jr W, et al. Risky driving in adolescents and young adults with childhood ADHD. J Pediatr Psychol 2007;32:745-759
13. Flory K, Molina BS, Pelham Jr WE, et al. Childhood ADHD predicts risky sexual behavior in young adulthood. J Clin Child Adolesc Psychol 2006;35:571-577
14. Arias AJ, Gelernter J, Chan G, et al. Correlates of co-occurring ADHD in drugdependent subjects: prevalence and features of substance dependence and psychiatric disorders. Addict Behav 2008;33:1199-1207
15. Fuemmeler BF, Kollins SH, McClernon FJ. Attention deficit hyperactivity disorder symptoms predict nicotine dependence and progression to regular smoking from adolescence to young adulthood. J Pediatr Psychol 2007; 32:1203-1213
16. Ernst M, Luckenbaugh DA, Moolchan ET, et al. Behavioral predictors of substance-use initiation in adolescents with and without attention-deficit/ hyperactivity disorder. Pediatrics 2006;117:2030-2039
17. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991;148:564-577
18. August GJ, Winters KC, Realmuto GM, et al. Prospective study of adolescent drug use among community samples of ADHD and non-ADHD participants. J Am Acad Child Adolesc Psychiatry 2006;45:824-832
19. Katusic SK, Barbaresi WJ, Colligan RC, et al. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol 2005;15:764-776
20. Mannuzza S, Klein RG, Truong NL, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective followup into adulthood. Am J Psychiatry 2008;165:604-609
21. Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm 2004;15:2391-2399
22. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108:e83
23. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-ofconcept, placebo-controlled studies of atomoxetine in children with attentiondeficit/hyperactivity disorder. J Clin Psychiatry 2002;63:1140-1147
24. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53: 112-120
25. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004;114:e1-8
26. Weiss M, Tannock R, Kratochvil C, et al. A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005;44:647-655
27. Cheng JY, Chen RY, Ko J, et al. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents: metaanalysis and meta-regression analysis. Psychopharmacology 2007;194: 197-209
28. Prasad S, Harpin V, Poole L, et al. A multi-centre, randomized, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Curr Med Res Opin 2007;23:379-394
29. Barton J, Mooney P, Prasad S. Atomoxetine hydrochloride and executive function in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2005;15:147-149
30. Wietecha LA, Williams DW, Herbert M, et al. Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:719-730
31. Eaton DK, Kann L, Kinchen S, et al. Youth Risk Behavior Surveillance-United States, 20 MMWR Surveill Summ 2006;55:1-108
32. Starfield B, Riley A, Ensminger M, et al. Manual for the Child Health and Illness Profile-Adolescent Edition. Baltimore, Maryland: The Johns Hopkins University, 1999
33. Saylor K, Buermeyer C, Sutton V, et al. The Life Participation Scale for Attention-Deficit/Hyperactivity Disorder-Child Version: psychometric properties of an adaptive change instrument. J Child Adolesc Psychopharmacol 2007;17:831-841
34. Evangelista NM, Owens JS, Golden CM, et al. The positive illusory bias: do inflated self-perceptions in children with ADHD generalize to perceptions of others? J Abnorm Child Psychol 2008;36:779-791
35. Owens JS, Hoza B. The role of inattention and hyperactivity/impulsivity in the positive illusory bias. J Consult Clin Psychol 2003;71:680-691
36. Owens JS, Goldfine ME, Evangelista NM, et al. A critical review of self-perceptions in children with ADHD. Clin Child Fam Psychol Rev 2007; 335-351
37. Adler L, Wilens T, Zhang S, et al. Retrospective safety analysis of atomoxetine in adult ADHD patients with or without comorbid alcohol abuse and dependence. Am J Addict 2009;18:393-401